News & Announcements
-
Director Dealing and Conversion of CLNs
/**/ RNS Number : 9734S IQ-AI Limited 09 November 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) Director Dealing and Conversion of Convertible Loan Notes IQ-AI Ltd has received a conversion notice from Trevor Brown, the CEO of IQ-AI, converting £100,000 convertible loan notes and associated interest, issued on 29 May 2019, at a price of 1.5
-
Application for Pediatric Rare Disease Designation
/**/ RNS Number : 8043S IQ-AI Limited 08 November 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Applies for FDA Pediatric Rare Disease Designation November 8, 2023, Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is pleased to announce it has submitted a Pediatric Rare Disease (“PRD”)
-
Holding(s) in Company
/**/ RNS Number : 5247S IQ-AI Limited 06 November 2023 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
-
Update Regarding Imaging Biometrics LLC
/**/ RNS Number : 5666Q IQ-AI Limited 18 October 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) IB Neuro Reveals the Hidden Secrets of High-Grade Glioma’s Invasive Margins October 18, 2023, Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a
-
IB Letter to Shareholders
/**/ RNS Number : 0709Q IQ-AI Limited 13 October 2023 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics LLC Letter to shareholders IQ-AI Limited (“IQAI”) (LSE: IQAI) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly owned